Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.68 |
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.68 |
| ▸ | TP53 | P04637 | 5/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.68 |
| ▸ | RECQL | P46063 | 4/20 | 0.68 |
| ▸ | CDK2 | P24941 | 4/20 | 0.68 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.68 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.67 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.64 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.64 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL505584 | 0.86 | MEN1 (0.79) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL10037939 | 0.84 | MEN1 (0.76) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL7659883 | 0.83 | MAPT (0.71) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL7656936 | 0.83 | MAPT (0.68) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL8019406 | 0.83 | MAPT (0.85) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL7655634 | 0.83 | MEN1 (0.68) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL7660823 | 0.83 | MEN1 (0.68) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL12941005 | 0.83 | MKNK2 (0.75) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL7658183 | 0.82 | SNCA (0.61) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL25207771 | 0.81 | MAPT (0.68) | MEN1KMT2AMAPTKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1109800-A1 | NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE | LG CHEMICAL LIMITED (KR) | 2001-06-27 | — | — | EP | claimed |
| WO-2000012496-A1 | NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE | LG CHEMICAL LTD. (KR) | 2000-03-09 | — | — | WO | claimed |
| US-9301965-B2 | Method of treating ovarian cancer using a PKC inhibitor | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301965-B2 | Method of treating ovarian cancer using a PKC inhibitor | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150366883-A1 | METHOD OF TREATING OVARIAN CANCER USING A PKC INHIBITOR | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150366883-A1 | METHOD OF TREATING OVARIAN CANCER USING A PKC INHIBITOR | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-6500846-B1 | 2-(4-CHLOROPHENYL)-7-METHOXYCHROMEN-4-ONE, AS CYCLIN-DEPENDENT KINASE INHIBITORS, USED AS ANTICARCINOGENIC AGENTS OR FOR PROPHYLAXIS OF NEURODEGENERATIVE DISEASE | LG CHEMICAL, LTD. (KR) | 2002-12-31 | — | — | US | disclosed |
| EP-1109800-A1 | NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE | LG CHEMICAL LIMITED (KR) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012496-A1 | NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE | LG CHEMICAL LTD. (KR) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366883-A1 | METHOD OF TREATING OVARIAN CANCER USING A PKC INHIBITOR | PRKD1, PRKCI, ACP3 | MEN1 2504/4885KMT2A 1552/4885MAPT 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.